Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring stage II prostate cancer, stage III prostate cancer, adenocarcinoma of the prostate
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate Clinical stage T1b-T3c disease No clinical or radiographic evidence of metastasis Prostate-specific antigen (PSA) less than 80 ng/mL Gleason score at least 5 One of the following criteria must be met: PSA greater than 10 ng/mL Gleason score greater than 6 T2b or greater palpable disease Three or more biopsy cores involved with a Gleason score of at least 5 PATIENT CHARACTERISTICS: Age Not specified Performance status Zubrod 0-1 Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified Other No other medical condition that would preclude study participation No other active malignancy within the past 5 years except nonmetastatic skin cancer or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic leukemia) Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy No more than 4 months of prior androgen deprivation therapy Neoadjuvant and adjuvant androgen deprivation therapy is allowed for high-risk disease only Radiotherapy No prior pelvic radiotherapy Surgery No prior or planned radical prostate surgery
Sites / Locations
- Fox Chase Cancer Center - Philadelphia
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
CIMRT
HIMRT
76 Gy in 38 fractions
70.2 Gy in 26 fractions